Was introduced early last year by Varian.

RapidArc, which delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient, was introduced early last year by Varian, the world leader in radiotherapy and software. Its introduction its launch more than 70 hospitals worldwide begun clinical treatments and PYNEH is the first in the South East Asia region, as it introduced the first image-guided radiotherapy to Hong Kong in 2006 was.

Varian is a leading supplier of tubes and digital detectors for X-ray imaging in medical, scientific and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America and Europe and its 60 sales and support offices around the world.

Dr. Said the hospital now plans of of RapidArc other other pelvic tumors and head and neck cancer are. PYNEH is one of six public cancer centers in Hong Kong.. About Varian Medical SystemsVarian Medical Systems, Palo Alto, California, is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy.The vaccine candidate is of the three attenuated influenza viruses of the World Health Organisation recommended to on seasonal A vaccine in an intranasal equipment along. To LAIV different from to most existing types of influenza vaccines, because it has been designed to offers single-dose intranasal, advanced cell culture Manufacturing and potential early and more comprehensive protection against infection by influenza virus.

Immunization of elderly in general has a lower impact on the prevalence, but is up to 80 percent be effective in preventing death. Nevertheless, Recent inactivated influenza vaccines who limits and is underutilized. Intramuscular immunization with needle is an essential obstacle to adoption of annual flu vaccination, can be overcome by intranasal administration. -the-art Influenza Vaccine attenuating is expected of being more efficient in inducing a local and cellular immunity and as such can be effectively in triggering protection.